New mRNA vaccine takes on tough cancers

NCT ID NCT07455617

Recruiting now Disease control Sponsor: Suzhou Abogen Biosciences Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial tests a new mRNA vaccine called ABO2102, designed to target cancers with specific KRAS mutations. About 101 adults with advanced solid tumors will receive the vaccine alone or with another drug (Sintilimab). The study focuses on safety and how the body responds, with a preliminary look at whether tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ABO2102 (mRNA vaccine targeting KRAS mutations) and Sintilimab (anti-PD-1 antibody)
What this could lead to: If successful, this could point toward a new treatment option for people with hard-to-treat cancers that have KRAS mutations.
What could go wrong: This is an early Phase 1 trial with only 101 participants, so the main goal is safety, not proof of effectiveness. The treatment may not shrink tumors or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED / METASTATIC SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED / METASTATIC SOLID TUMOR

Contacts and locations

Locations

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.